IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PUOTI, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.460
EU - Europa 1.904
AS - Asia 1.523
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 13
AF - Africa 9
SA - Sud America 4
Totale 8.927
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.441
CN - Cina 841
UA - Ucraina 740
DE - Germania 366
SG - Singapore 283
FI - Finlandia 191
HK - Hong Kong 188
IT - Italia 172
TR - Turchia 118
GB - Regno Unito 114
IE - Irlanda 112
PL - Polonia 100
IN - India 71
FR - Francia 45
SE - Svezia 28
CA - Canada 19
BE - Belgio 15
EU - Europa 13
AU - Australia 12
IR - Iran 9
JP - Giappone 4
MU - Mauritius 4
NL - Olanda 4
RU - Federazione Russa 4
LA - Repubblica Popolare Democratica del Laos 3
ZA - Sudafrica 3
BG - Bulgaria 2
BR - Brasile 2
CZ - Repubblica Ceca 2
HU - Ungheria 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
CL - Cile 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
ID - Indonesia 1
LR - Liberia 1
LT - Lituania 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
Totale 8.927
Salva come PNG Salva come JPEG
Città #
Woodbridge 766
Fairfield 665
Jacksonville 553
Houston 477
Ashburn 458
Ann Arbor 336
Wilmington 335
Cambridge 310
Seattle 298
Nanjing 227
Singapore 224
Princeton 193
Hong Kong 188
Chandler 177
Dublin 112
Istanbul 100
Warsaw 100
Nanchang 88
Beijing 84
Helsinki 84
Dearborn 80
Shenyang 59
New York 57
Des Moines 52
San Diego 46
Changsha 43
Tianjin 42
Hebei 41
Shanghai 38
Jiaxing 36
Jinan 36
Milan 33
Lancaster 32
Brescia 30
Washington 26
Los Angeles 23
Verona 21
Kunming 19
London 18
Taizhou 16
Toronto 16
Brussels 15
Hangzhou 15
Kocaeli 15
Zhengzhou 15
Lanzhou 14
Munich 14
Leawood 13
San Francisco 13
San Mateo 13
Haikou 11
Monmouth Junction 11
Norwalk 11
Augusta 9
Ningbo 9
Ardabil 8
Melbourne 8
Guangzhou 7
Orange 6
Taiyuan 6
Fuzhou 5
Hefei 5
Rome 4
Tokyo 4
Boardman 3
Charlotte 3
Grafing 3
Gunzenhausen 3
Kilburn 3
Messina 3
Rende 3
Sydney 3
Vientiane 3
Auburn Hills 2
Auckland 2
Bologna 2
Bratislava 2
Brno 2
Catania 2
Chicago 2
Clifton 2
Crotone 2
Dong Ket 2
Frankfurt am Main 2
Hanover 2
Hounslow 2
Mumbai 2
Oklahoma City 2
Ottawa 2
Polaveno 2
Redmond 2
Roccafranca 2
Ronciglione 2
Sofia 2
Almere Stad 1
Athens 1
Baotou 1
Berlin 1
Budapest 1
Cairo 1
Totale 6.845
Salva come PNG Salva come JPEG
Nome #
Use of brain MRI in manganese exposure 153
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients 144
Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial 140
Antiretroviral drugs and liver injury. 132
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 124
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 122
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 122
A meta-analysis of epidemiological studies on the combined effect of hepatitis-B and -C virus infections in causing hepatocellular carcinoma. 121
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 117
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 112
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. 112
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 112
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 111
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 109
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 108
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. 105
Mortality for liver disease in patients with HIV infection: a cohort study 104
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel 103
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 102
Polymorphic immune restoration syndrome after effective HAART 102
Care of patients with hepatitis C and HIV co-infection. 101
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 101
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. 100
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 99
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 99
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C?A gender-oriented analysis. 99
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 98
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 95
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 94
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. 94
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 94
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. 93
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. 92
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 91
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 90
Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? 90
Statements from the Taormina expert meeting on occult hepatitis B virus infection. 90
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 89
The burden of HIV and hepatitis C virus coinfection. 89
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study 88
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 88
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 87
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. 87
Natural history of chronic hepatitis B in co-infected patients. 87
Hepatitis B Virus Co-infection in Human Immunodeficiency Virus- infected Subjects 86
The use of molecular assays in the management of viral hepatitis. 86
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 86
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 86
HCV chronic hepatitis in patients with HIV: clinical management issues 85
Management of hepatitis C in human immunodeficiency virus-infected patients. 85
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. 85
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 84
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 84
Impact of hepatitis C virus infection on lifestyle. 83
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 83
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 82
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. 82
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 82
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 82
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 82
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 79
HIV/HCV co-infection: natural history. 78
The T-cell receptor repertoires expressed by CD4+ and CD4- large granularlymphocytes derived from the same patients suggest the persistent action of animmune-mediated selection process 78
Comment to the Editorial: Liver biopsy in HIV-infected pateints with chronic hepatitis C: pros and cons, by V. Soriano and J. Garcia Samaniego 77
The attributable risk of hepatocarcinoma for the Hepatitis B and C virus infections in a high-incidence area in North Italy: a case-control study. 77
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 77
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: disegno dello studio. 76
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 76
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 76
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy 75
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 75
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 73
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 71
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 70
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 70
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 69
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 69
Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV infected patients: a prospective cohort study 68
Insulino-resistenza in pazienti HCV positivi sottoposti a trattamento antivirale in uno studio di coorte multicentrico: dati preliminari. 68
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 66
Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) 66
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection-statements of the First Italian Consensus Workshop. 65
Ruolo dell'infezione occulta da virus dell'epatite B nell'evoluzione dell'epatite cronica da virus C attraverso uno studio di coorte multicentrico: dati preliminari. 64
Targeted screening for viral epatiti in an italian community of 100.000 inhabitants 64
Indagine sulla suscettibilità genetica nella risposta al trattamento antivirale di soggetti con epatite cronica da virus c attraverso uno studio di coorte multicentrico: disegno dello studio. 63
Insulin resistance is not a relevant predictor of sustaned virologic response (SVR) in chronic hepatitis c (CHC) patients treated with pegylated interferon (peg-ifn) and ribavirin. 62
Co-infezione HIV-HCV e dislipidemie in corso di terapia antiretrovirale ad elevata efficacia (HAART) 60
HCV infection: pathogenesis, clinical manifestations and therapy. 57
I Data-Base clinici e la sorveglianza degli eventi avversi alla HAART: il Progetto MASTER 56
Pathogenesis of liver damage in HCV-HIV patients. 56
Hepatotoxicity associated with non nucleoside reverse trasciptase inhibitors (NNRTI) in 427 adults infected with Human Immunodeficiency Virus. 55
Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. 55
Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection 54
Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study 53
Hepatitis C viral kinetics in HIV co-infected patients during combination treatment with interferon and ribavirin 52
Prevalence des marqueurs du virus de l'hepatite B et des anticorps contre le virus de l'hepatite C parmi le personnel du District sanitaire de Nanoro, Burkina Faso 52
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3 51
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. 50
Stima della prevalenza di malattie epatiche e della loro eziologia in un'area ad alta incidenza mediante utilizzo di dati correnti. 50
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 50
Totale 8.536
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.484
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.484
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.616 0 0 0 0 140 287 227 260 163 338 49 152
2020/20211.463 17 165 32 224 51 149 82 155 244 110 196 38
2021/2022834 52 128 1 46 3 46 40 55 35 119 86 223
2022/2023654 112 8 10 31 49 207 0 70 90 7 31 39
2023/2024786 42 16 71 81 45 141 31 36 199 14 2 108
2024/2025461 8 4 7 237 205 0 0 0 0 0 0 0
Totale 9.033